Literature DB >> 30281371

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma.

Stephanie L Skala, Saravana M Dhanasekaran, Rohit Mehra1.   

Abstract

CONTEXT.—: Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance. OBJECTIVE.—: To review classic morphologic features of HLRCC-associated renal cell carcinoma, the reported morphologic spectrum of these tumors and their mimics, and the evidence for use of immunohistochemistry and molecular testing in diagnosis of these tumors. DATA SOURCES.—: University of Michigan cases and review of pertinent literature about HLRCC and the morphologic spectrum of HLRCC-associated renal cell carcinoma. CONCLUSIONS.—: Histologic features, such as prominent nucleoli with perinucleolar halos and multiple architectural patterns within one tumor, are suggestive of HLRCC-associated renal cell carcinoma. However, the morphologic spectrum is broad. Appropriate use of FH immunohistochemistry and referral to genetic counseling is important for detection of this syndrome.

Entities:  

Mesh:

Year:  2018        PMID: 30281371     DOI: 10.5858/arpa.2018-0216-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

Review 1.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options.

Authors:  Karren Antonio; Ma Margarita Noreen Valdez; Leilani Mercado-Asis; David Taïeb; Karel Pacak
Journal:  Gland Surg       Date:  2020-02

Review 3.  [Histological subtypes of renal cell carcinoma : Overview and new developments].

Authors:  I Polifka; A Agaimy; H Moch; A Hartmann
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

Review 4.  Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

Authors:  Panagiotis Zoumpourlis; Giannicola Genovese; Nizar M Tannir; Pavlos Msaouel
Journal:  Clin Genitourin Cancer       Date:  2020-12-02       Impact factor: 2.872

Review 5.  Application Areas of Traditional Molecular Genetic Methods and NGS in relation to Hereditary Urological Cancer Diagnosis.

Authors:  Dmitry S Mikhaylenko; Alexander S Tanas; Dmitry V Zaletaev; Marina V Nemtsova
Journal:  J Oncol       Date:  2020-06-17       Impact factor: 4.375

6.  Hereditary leiomyomatosis and renal cell cancer syndrome - case report and review of the literature.

Authors:  Liliana Gabriela Popa; Raluca Silvia Lutuc; Mara Mădălina Mihai; Irina Ahmed Salem; Silvius Ioan Negoiţă; Călin Giurcăneanu; Simona Vasilica Fica
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

7.  Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.

Authors:  Ling Yang; Xue-Ming Li; Ya-Jun Hu; Meng-Ni Zhang; Jin Yao; Bin Song
Journal:  Korean J Radiol       Date:  2021-09-24       Impact factor: 3.500

8.  Hereditary Leiomyomatosis and Renal Cell Cancer.

Authors:  Anders Würgler Hansen; Zahràa Chayed; Kristine Pallesen; Ileana Codruta Vasilescu; Anette Bygum
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

9.  Fumarate hydratase c.914T > C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome.

Authors:  Kelsey E Breen; Maria I Carlo; Yelena Kemel; Anna Maio; Ying-Bei Chen; Liying Zhang; Ozge Ceyhan-Birsoy; Diana Mandelker
Journal:  Mol Genet Genomic Med       Date:  2020-05-28       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.